Overview

Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

JTX-8064-101 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).

Phase:

Phase 1

Details

Lead Sponsor:

Jounce Therapeutics, Inc.

Treatments:

Pembrolizumab